2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3161

Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Abstract Number: 146

Rates of Lipid Testing and Statin Prescription Filling Among U.S. Medicaid Recipients with SLE, 2007-2010
Abstract Number: 2971

Raynaud Phenomenon Subjects with Abnormal Capillary Dilations Show a Risk Threshold Diameter Value for the Transition to the Capillaroscopic Early� Scleroderma Pattern: A Case Control Study
Abstract Number: 2294

Re-Scoring the 2011 Fibromyalgia Survey Criteria to be a Better Surrogate for Pain Centralization
Abstract Number: 1323

Reaching Consensus – Volumetric Joint Space Width Calculations in Finger Joints of Arthritis Patients
Abstract Number: 1513

Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients
Abstract Number: 1809

Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Abstract Number: 2745

Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
Abstract Number: 2880

Real-World Impact of Anti-TNF Medication Use on Patient Reported Outcomes in a Prospective Cohort of Patients with Ankylosing Spondylitis
Abstract Number: 2610

Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up
Abstract Number: 2346

Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1b Production through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells
Abstract Number: 3101

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Sclerostin Are Related to Joint Destruction in Early Rheumatoid Arthritis Unrelated to Polymorphisms of the Genes
Abstract Number: 2133

Receptor Protein Tyrosine Phosphatase Alpha Enhances Rheumatoid Synovial Fibroblast Signaling and Promotes Arthritis in Mice
Abstract Number: 1762

Reciprocal Roles of Intestinal Microbiota in the Pathogenesis of Organ-Specific Autoimmune Diseases in a Lymphopenia-Induced Autoimmunity Mouse Model
Abstract Number: 1832

Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].